ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf

ACADIA Pharmaceuticals (NASDAQ:ACAD) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to highlight ...

Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced multiple business updates and progress on the Company's ...
Business Wire

ACADIA Pharmaceuticals Announces Appointment of Michael J. Yang as Executive Vice President, Chief Commercial Officer

SAN DIEGO--(BUSINESS WIRE)--ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical ...
Business Wire

Acadia Pharmaceuticals Appoints Thomas Garner Chief Commercial Officer

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead ...
FiercePharma

Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO). The company is looking to consolidate its older drug, Nuplazid, while boosting its ...
Odessa American

Acadia Pharmaceuticals Announces Commercial Leadership Change

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Michael Yang, Executive Vice President and Chief Commercial Officer, will be leaving the organization effective January 29, 2021 to ...